Pharmacological characterization of the selective 11β-hydroxysteroid dehydrogenase 1 inhibitor, BI 135585, a clinical candidate for the treatment of type 2 diabetes.

Abstract

To combat the increased morbidity and mortality associated with the developing diabetes epidemic new therapeutic interventions are desirable. Inhibition of intracellular cortisol generation from cortisone by blocking 11β-hydroxysteroid dehydrogenase 1 (11β-HSD1) has been shown to ameliorate the risk factors associated with the metabolic syndrome. A… (More)
DOI: 10.1016/j.ejphar.2014.10.053

Topics

Cite this paper

@article{Hamilton2015PharmacologicalCO, title={Pharmacological characterization of the selective 11β-hydroxysteroid dehydrogenase 1 inhibitor, BI 135585, a clinical candidate for the treatment of type 2 diabetes.}, author={Bradford S. Hamilton and Frank Himmelsbach and Herbert Nar and Annette Schuler-Metz and Paula M Krosky and Joan Guo and Rong Guo and Shi Jie Meng and Yi Zhao and Deepak S Lala and Linghang Zhuang and David A. Claremon and Gerard M. McGeehan}, journal={European journal of pharmacology}, year={2015}, volume={746}, pages={50-5} }